SOMERSET, N.J. & COPENHAGEN, Denmark – The European Commission has unconditionally approved the acquisition of Catalent, Inc. (NYSE: NYSE:), a prominent player in the development and supply of pharmaceutical treatments, by Novo Holdings A/S, a global investment firm specializing in life sciences. This regulatory clearance marks a significant step towards the completion of the transaction, which is anticipated to finalize by the end of 2024.

Catalent’s President and CEO, Alessandro Maselli, expressed gratitude for the Catalent team’s commitment, indicating the company’s bright future as a private entity with Novo Holdings’ backing. Jonathan Levy, Senior Partner at Novo Holdings, echoed the sentiment, looking forward to supporting Catalent’s continued value creation for stakeholders and improved patient outcomes.

The closure of the deal is contingent on other customary closing conditions, including the receipt of all necessary regulatory clearances.

Catalent, with headquarters in Somerset, New Jersey, is recognized for its extensive capabilities in development sciences, delivery technologies, and manufacturing across various modalities. The company boasts a global footprint with over 50 sites and an approximate annual revenue of $4.4 billion for the fiscal year 2024, maintaining a healthy current ratio of 2.51. InvestingPro subscribers can access 8 additional key insights and a comprehensive Pro Research Report, which provides deep-dive analysis of Catalent’s financial health and market position. Catalent supports the development and launch of numerous partner programs and products each year.

Novo Holdings, owned by the Novo Nordisk (NYSE:) Foundation, manages a diverse investment portfolio, including life sciences companies across all development stages. As of the end of 2023, Novo Holdings reported total assets of EUR 149 billion.

The financial advisors for Catalent in this transaction were Citi and J.P. Morgan, with Skadden, Arps, Slate, Meagher & Flom LLP and Jones Day providing legal counsel. Novo Holdings enlisted Morgan Stanley (NYSE:) & Co. LLC for financial advice and Goodwin Procter LLP and Linklaters LLP for legal matters.

This news announcement is based on a press release statement and does not include any speculative or promotional content. It presents the factual details of the European Commission’s approval of the acquisition of Catalent by Novo Holdings, a transaction that holds significance for both entities and their stakeholders within the life sciences industry. For investors seeking deeper insights, InvestingPro offers comprehensive analysis of Catalent’s market position, including detailed financial metrics and expert-curated ProTips that help inform investment decisions.

In other recent news, Catalent, a contract drug manufacturer, reported a first-quarter revenue of $1.02 billion, falling short of Wall Street expectations. The Biologics segment of the business underperformed, generating $461 million compared to the anticipated $470.57 million. Jefferies maintains a hold rating on Catalent with a $63.50 target, following disappointing first-quarter results, particularly in the Biologics revenue and margin. The firm revised its fiscal year 2025 revenue and EBITDA estimates for Catalent downwards. Meanwhile, the company is in the process of being acquired by Novo Holdings in a deal valued at $16.5 billion, expected to finalize by the end of 2024. Catalent CEO, Alessandro Maselli, affirmed his commitment to continue leading the company post-acquisition. These are some of the recent developments concerning Catalent.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.